OS Therapies Incorporated (OSTX) AI Stock Analysis

• Market Cap: $50.71M
• Dividend Yield: N/A
• Average Volume (3M): 482.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.07
• Revenue Growth: N/A
• EPS Growth: -133.00%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 35,214,350
• 10 Day Avg. Volume: 551,595
• 30 Day Avg. Volume: 482,092
• PEG Ratio: -0.30
• Price to Book (P/B): -17.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.27
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -258.12
• Enterprise Value/Ebitda: -3.43
• 1Y Price Target: $11.50
• Price Target Upside: 698.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▲(4.17% Upside)

The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn) and negative-to-neutral technical momentum (below key moving averages with negative MACD). A recent capital raise that reportedly extends runway into 2027 helps mitigate near-term liquidity risk, but valuation remains constrained by ongoing losses and the lack of a dividend.

Positive Factors

Debt-Free Balance Sheet

A debt-free balance sheet enhances financial flexibility, allowing OS Therapies to focus resources on R&D and strategic initiatives without the burden of interest payments.

Improved Capital Structure

The positive equity position reflects a stronger capital structure, which can support future fundraising efforts and improve investor confidence in the company's financial health.

Strategic Corporate Actions

These strategic actions enhance funding flexibility and governance, positioning the company to better manage future capital needs and protect shareholder interests.

Negative Factors

No Revenue and Expanding Losses

The lack of revenue and increasing losses highlight the company's ongoing struggle to achieve commercial traction, posing a risk to long-term sustainability without successful product development.

Significant Cash Burn

The substantial cash burn underscores the need for continued external funding, which could lead to dilution and affect shareholder value if not managed effectively.

Dilution Risk

While increasing authorized shares provides funding flexibility, it also poses a risk of dilution, which can reduce existing shareholders' equity and impact stock value.

OS Therapies Incorporated Business Overview & Revenue Model

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

How the Company Makes Money

OS Therapies Incorporated generates revenue primarily through the commercialization of its proprietary therapies once they receive regulatory approval. The company engages in strategic partnerships and licensing agreements with larger pharmaceutical companies to co-develop and market its treatments, thereby earning revenue through upfront payments, milestone achievements, and royalties on sales. Additionally, OS Therapies may receive funding through grants and research collaborations with academic institutions and government agencies, which support its ongoing research and development efforts.

OS Therapies Incorporated Financial Statement Overview

Summary

OS Therapies Incorporated is experiencing significant financial challenges, characterized by a lack of revenue, increasing net losses, and negative operating cash flows. While there is a notable improvement in equity position and liquidity in 2024, the financial stability remains weak due to past leverage and ongoing operational losses. The company's reliance on external financing to sustain operations suggests potential risks if future fundraising efforts do not meet cash requirements.

Income Statement

OS Therapies Incorporated has reported no revenue for the past several years, indicating no income generation from operations. The company has consistently incurred significant net losses, with an increasing trend in net losses from -7.42 million USD in 2021 to -8.88 billion USD in 2024. This trend suggests a lack of profitability and potential challenges in revenue generation and cost management.

Balance Sheet

The company's balance sheet shows high cash reserves of 5.53 billion USD in 2024, indicating strong liquidity. However, the equity is negative in prior years, but significantly positive in 2024 at 6.05 billion USD, suggesting a recent capital injection or debt restructuring. The absence of total debt in 2024 improves the debt-to-equity ratio, though previous years show very high leverage with negative equity, indicating financial instability and potential risk in managing liabilities.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing cash usage in operations without any revenue inflow. The free cash flow has worsened from -3.79 million USD in 2022 to -7.28 billion USD in 2024, indicating increasing operational cash demands. Positive financing cash flow in 2024 suggests reliance on external financing to support cash needs, highlighting a potential risk if financing sources become restricted.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-239.54K	-2.78K	-4.22K	-805.00	-1.16M	-4.25K
EBITDA	-18.04M	-6.83M	-4.34M	-4.45M	-4.84M	-5.65K
Net Income	-18.28M	-8.88M	-7.79M	-6.25M	-7.42M	-6.03K
Balance Sheet
Total Assets	8.95M	5.54M	798.08K	509.11K	325.89K	1.68B
Cash, Cash Equivalents and Short-Term Investments	1.88M	5.53M	38.98K	171.48K	80.79K	1.23B
Total Debt	0.00	0.00	14.61M	10.35M	7.07M	6.77B
Total Liabilities	4.25M	4.73M	24.81M	18.07M	11.78M	8.00B
Stockholders Equity	4.71M	811.49K	-24.02M	-17.56M	-11.45M	-6.33B
Cash Flow
Free Cash Flow	-13.35M	-7.28M	-3.01M	-3.79M	-4.41M	-2.42B
Operating Cash Flow	-12.88M	-7.28M	-3.01M	-3.79M	-4.40M	-2.41B
Investing Cash Flow	-466.42K	0.00	1.15K	230.88K	200.47K	158.29M
Financing Cash Flow	13.37M	12.78M	2.87M	3.65M	3.05M	3.48B

OS Therapies Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANVS	46 Neutral	$91.43M	-2.10	-246.14%	―	―	62.84%
GANX	46 Neutral	$82.31M	-3.49	-261.72%	―	―	42.29%
OSTX	45 Neutral	$50.71M	-1.89	-914.04%	―	―	-133.00%
ATNM	45 Neutral	$40.55M	-1.22	-133.09%	―	11.11%	20.65%

OS Therapies Incorporated Corporate Events

OS Therapies Raises Capital Through Warrant Inducement Agreements

On January 10, 2026, OS Therapies entered into warrant inducement agreements with nine accredited investors holding existing warrants, securing the exercise or pre‑funding of all such warrants at a reduced $1.40 exercise price in exchange for new five‑year warrants on the same pricing terms. The transaction, announced on January 12, 2026 and supported by Ceros Capital Markets as solicitation agent, generated approximately $7.53 million in gross proceeds, extending the company’s cash runway into 2027 and funding regulatory submissions and commercial preparations for OST‑HER2 in metastatic osteosarcoma across the U.S., U.K. and EU, as well as preparations for the proposed spinoff of its OS Animal Health subsidiary and general corporate needs, thereby strengthening its balance sheet and addressing prior market concerns about liquidity while deepening backing from long‑term investors.

The most recent analyst rating on (OSTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

OS Therapies Approves Key Proposals at Annual Meeting

On October 21, 2025, OS Therapies Incorporated held its annual meeting where stockholders approved several key proposals. These included the election of six directors, an amendment to increase the company’s authorized shares, and a shareholder rights agreement. The meeting also saw the approval of an incentive compensation plan amendment and the ratification of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect strategic moves to enhance the company’s operational capabilities and shareholder value.

The most recent analyst rating on (OSTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

OS Therapies Releases Investor Presentation for Stakeholders

On October 17, 2025, OS Therapies Incorporated announced the posting of an investor presentation on their website, which they plan to use in discussions with investors and analysts. The company also held its annual meeting of stockholders on October 14, 2025, where key proposals were approved, but the meeting was adjourned to allow more time for proxy solicitation. The reconvened meeting is scheduled for October 21, 2025. This strategic move is part of OS Therapies’ efforts to engage stakeholders and ensure comprehensive participation in its decision-making processes.

The most recent analyst rating on (OSTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.